A systematic review and economic evaluation of statins for the prevention of coronary events
Open accessThe DOI matches its Crossref record; 342 of the 356 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: To evaluate the clinical effectiveness and cost-effectiveness of statins for the primary and secondary prevention of cardiovascular events in adults with, or at risk of, coronary heart disease (CHD). DATA SOURCES: Electronic databases were searched between November 2003 and April 2004. REVIEW METHODS: A review was undertaken to identify and evaluate all literature relating to the clinical and cost effectiveness of statins in the primary and secondary prevention of CHD and cardiovascular disease (CVD) in the UK. A Markov model was developed to explore the costs and health outcomes associated with a lifetime of statin treatment using a UK NHS perspective. RESULTS: Thirty-one randomised studies were identified that compared a statin with placebo or with another statin, and reported clinical outcomes. Meta-analysis of the available data from the placebo-controlled studies indicates that, in patients with, or at risk of, CVD, statin therapy is associated with a reduced relative risk of all cause mortality, cardiovascular mortality, CHD mortality and fatal myocardial infarction (MI), but not of fatal stroke. It is also associated with a reduced relative risk of morbidity [non-fatal stroke, non-fatal MI, transient ischaemic attack (TIA), unstable angina] and of coronary revascularisation. It is hardly possible, on the evidence available from the placebo-controlled trials, to differentiate between the clinical efficacy of atorvastatin, fluvastatin, pravastatin and simvastatin. However, there is some evidence from direct comparisons between statins to suggest that atorvastatin may be more effective than pravastatin in patients with symptomatic CHD. There is limited evidence for the effectiveness of statins in different subgroups. Statins are generally considered to be well tolerated and to have a good safety profile. This view is generally supported both by the evidence of the trials included in this review and by postmarketing surveillance data. Increases in creatine kinase and myopathy have been reported, but rhabdomyolysis and hepatotoxicity are rare. However, some patients may receive lipid-lowering therapy for as long as 50 years, and long-term safety over such a timespan remains unknown. In secondary prevention of CHD, the incremental cost-effectiveness ratios (ICERs) increase with age varying between pound 10,000 and pound 17,000 per quality adjusted life year (QALY) for ages 45 and 85 respectively. Sensitivity analyses show these results are robust. In primary prevention of CHD there is substantial variation in ICERs by age and risk. The average ICERs weighted by risk range from pound 20,000 to pound 27,500 for men and from pound 21,000 to pound 57,000 for women. The results are sensitive to the cost of statins, discount rates and the modelling time frame. In the CVD analyses, which take into account the benefits of statins on reductions in stroke and TIA events, the average ICER weighted by risk level remains below pound 20,000 at CHD risk levels down to 0.5%. Limitations of the analyses include the requirement to extrapolate well beyond the timeframe of the trial period, and to extrapolate effectiveness results from higher risk primary prevention populations to the treatment of populations at much lower risk. Consequently, the results for the lower age bands and lower risks are subject to greater uncertainty and need to be treated with caution. CONCLUSIONS: There is evidence to suggest that statin therapy is associated with a statistically significant reduction in the risk of primary and secondary cardiovascular events. As the confidence intervals for each outcome in each prevention category overlap, it is not possible to differentiate, in terms of relative risk, between the effectiveness of statins in primary and secondary prevention. However, the absolute risk of CHD death/non-fatal MI is higher, and the number needed to treat to avoid such an event is consequently lower, in secondary than in primary prevention. The generalisability of these results is limited by the exclusion, in some studies, of patients who were hypersensitive to, intolerant of, or known to be unresponsive to, statins, or who were not adequately compliant with study medication during a placebo run-in phase. Consequently, the treatment effect may be reduced when statins are used in an unselected population. The results of the economic modelling show that statin therapy in secondary prevention is likely to be considered cost-effective. In primary prevention, the cost-effectiveness ratios are dependent on the level of CHD risk and age, but the results for the CVD analyses offer support for the more aggressive treatment recommendation issued by recent guidelines in UK. Evidence on clinical endpoints for rosuvastatin is awaited from on-going trials. The potential targeting of statins at low-risk populations is however associated with major uncertainties, particularly the likely uptake and long-term compliance to lifelong medica
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce. 7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Most studies assessing the cost-effectiveness of prevention of CVD combine evidence from clinical research with simulation approaches, while data from randomized controlled trials (RCTs) are relatively scarce.7,10,11”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Lowering blood cholesterol levels using statins 10,11,23-25 and improving blood pressure control are also cost effective. 26,27”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [11]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Part of this paper’s reference list could not be split into single entries.
Items 201–342 of 342
Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease
Nissen, S. E., Tuzcu, E. M., & Schoenhagen, P. (2005) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2005.01.024 · Cited by 65
Pauciullo, P., Borgnino, C., Paoletti, R., Mariani, M., & Mancini, M. (2000) · Atherosclerosis · doi:10.1016/s0021-9150(00)00379-8 · Cited by 64
Cholesterol and coronary heart disease: screening and treatment
Ebrahim, S., Smith, G. D., McCabe, C., Payne, N., Pickin, M., Sheldon, T. A., Lampe, F., Sampson, F., Ward, S., & Wannamthee, G. (1998) · Quality and Safety in Health Care · doi:10.1136/qshc.7.4.232 · Cited by 63
Self-citationChambers, M., Hutton, J., & Gladman, J. R. F. (1999) · PharmacoEconomics · doi:10.2165/00019053-199916050-00013 · Cited by 62
Comparison of efficacy and safety of atorvastatin (10 mg) with simvastatin (10 mg) at six weeks
Insull, W., Kafonek, S. D., Goldner, D., & Zieve, F. J. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01430-2 · Cited by 62
Marshall, T. P., & Rouse, A. (2002) · BMJ · doi:10.1136/bmj.325.7357.197 · Cited by 61
Williams, B., Poulter, N. R., Mj, B., Davis, M. R., & Sever, P. (2004) · Cited by 61
Effects of metoprolol vs verapamil in patients with stable angina pectoris
Rehnqvist, N., Hjemdahl, P., Billing, E., Björkander, I., Eriksson, S. V., Forslund, L., Held, C., Näsman, P., & Wallén, N. H. (1996) · European Heart Journal · Cited by 61
Fisher, C. M. (2002) · New England Journal of Medicine · doi:10.1056/nejmp020129 · Cited by 60
Nawawi, H. M., Osman, N. S., Yusoff, K., & Khalid, B. A. K. (2003) · Hormone and Metabolic Research · doi:10.1055/s-2003-41805 · Cited by 58
Quality of life and time trade-off utility measures in patients with coronary artery disease
Melsop, K. A., Boothroyd, D. B., & Hlatky, M. A. (2003) · American Heart Journal · doi:10.1067/mhj.2003.37 · Cited by 57
Effect of partial compliance on cardiovascular medication effectiveness
Cramer, J. A. (2002) · Heart · doi:10.1136/heart.88.2.203 · Cited by 57
Farnier, M., & Dejager, S. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00606-2 · Cited by 56
Schwartz, G. G., Bolognese, M. A., Tremblay, B., Caplan, R. J., Hutchinson, H. G., Raza, A., & Cressman, M. D. (2004) · American Heart Journal · doi:10.1016/j.ahj.2004.01.020 · Cited by 55
Winkler, K., Abletshauser, C., Hoffmann, M. M., Friedrich, I., Baumstark, M. W., Wieland, H., & März, W. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-020370 · Cited by 55
Renders, L., Mayer‐Kadner, I., Koch, C., Schärffe, S., Burkhardt, K., Veelken, R. A., Schmieder, R. E., & Hauser, I. A. (2001) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/16.1.141 · Cited by 54
Wierzbicki, A. S., Lumb, P., Chik, G., & Crook, M. A. (1999) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1999.tb11815.x · Cited by 54
As a matter of fact: evidence-based decision-making unplugged
Birch, S. (1997) · Health Economics · doi:10.1002/(sici)1099-1050(199711)6:6<589::aid-hec286>3.0.co;2-d · Cited by 53
Coronary heart disease prevention: insights from modelling incremental cost effectiveness
Marshall, T. (2003) · BMJ · doi:10.1136/bmj.327.7426.1264 · Cited by 53
Fluvastatin long-term extension trial (FLUENT): Summary of efficacy and safety
Davidson, M. (1994) · The American Journal of Medicine · doi:10.1016/0002-9343(94)90231-3 · Cited by 53
A Model for Evaluating the Cost-Effectiveness of Cholesterol-Lowering Treatment
Glick, H. A., Heyse, J. F., Thompson, D., Epstein, R. S., Smith, M. E., & Oster, G. (1992) · International Journal of Technology Assessment in Health Care · doi:10.1017/s0266462300002403 · Cited by 52
Unit Costs of Health and Social Care 2004
Selwyn, J., Sturgess, W., Quinton, D., & Baxter, C. (2004) · Cited by 52
Patients’ Perspectives on Statin Therapy for Treatment of Hypercholesterolaemia: A Qualitative Study
Tolmie, E. P., Lindsay, G., Kerr, S., Brown, M., Ford, I., & Gaw, A. (2003) · European Journal of Cardiovascular Nursing · doi:10.1016/s1474-5151(03)00028-8 · Cited by 51
Watts, G. F., Chan, D. C., Barrett, P. H. R., O’Neill, F. H., & Thompson, G. R. (2003) · International Journal of Obesity · doi:10.1038/sj.ijo.0802287 · Cited by 50
Heinonen, T., Stein, E., Weiss, S., Mckenney, J., Davidson, M., Shurzinske, L., & Black, D. (1996) · Clinical Therapeutics · doi:10.1016/s0149-2918(96)80045-2 · Cited by 50
März, W., Wollschläger, H., Klein, G., Neiß, A., & Wehling, M. (1999) · The American Journal of Cardiology · doi:10.1016/s0002-9149(99)00183-6 · Cited by 49
Magnani, G., Carinci, V., Magelli, C., Potena, L., Reggiani, M. L. B., & Branzi, A. (2000) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(00)00128-5 · Cited by 48
Muls, E., Ganse, E. H. V., & Closon, M.-C. M.-C. C. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(97)00321-3 · Cited by 47
Nora, E. D., Passaro, A., Zamboni, P., Calzoni, F., Fellin, R., & Solini, A. (2003) · Journal of Endocrinological Investigation · doi:10.1007/bf03345126 · Cited by 47
Haq, I. U. (1999) · QJM · doi:10.1093/qjmed/92.7.379 · Cited by 47
Cc, W., Sy, R., Tanphaichitr, V., At, H., Suyono, S., & Yt, L. (2002) · PubMed · Cited by 46
Gross, J. B. (2004) · Survey of Anesthesiology · doi:10.1097/01.sa.0000119601.77789.60 · Cited by 45
Antiarrhythmic Therapies for the Prevention of Sudden Cardiac Death
McAlister, F. A., & Teo, K. K. (1997) · Drugs · doi:10.2165/00003495-199754020-00003 · Cited by 45
Carcinogenicity of lipid-lowering drugs
Newman, T. B. (1996) · JAMA · doi:10.1001/jama.275.1.55 · Cited by 45
Use of statins in general practices, 1996-8: cross sectional study
Packham, C., Pearson, J., Robinson, J., & Gray, D. (2000) · BMJ · doi:10.1136/bmj.320.7249.1583 · Cited by 43
Statin prescribing in Nottingham general practices: a cross-sectional study
Packham, C., Robinson, J., Morris, J., Richards, C., Marks, P., & Gray, D. P. (1999) · Journal of Public Health · doi:10.1093/pubmed/21.1.60 · Cited by 43
Farnier, M., Salko, T., Isaacsohn, J. L., Troendle, A. J., Dejager, S., & Gonasun, L. M. (2003) · The American Journal of Cardiology · doi:10.1016/s0002-9149(03)00885-3 · Cited by 41
Elliott, W. J., & Weir, D. R. (1999) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/56.17.1726 · Cited by 41
Pravastatin therapy and the risk of stroke
White, H. D., Simes, R. J., & Anderson, N. E. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(00)00169-0 · Cited by 41
Insull, W., Black, D., Dujovne, C., Hosking, J. D., Hunninghake, D., Keilson, L., Knopp, R., McKenney, J., Stein, E., & Troendle, A. J. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.1994.00420210087010 · Cited by 41
Colivicchi, F., Guido, V., Marco Tubaro, U., Ammirati, F., MONTEFOSCHI, N., Varveri, A., & Santini, M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(02)02711-x · Cited by 40
Carlsson, C. M., Papcke-Benson, K., Carnes, M. L., McBride, P. E., & Stein, J. H. (2002) · Drugs & Aging · doi:10.2165/00002512-200219100-00008 · Cited by 40
Raggi, P., Callister, T. Q., Davidson, M. H., Welty, F. K., Bachmann, G. A., Laskey, R. E., Pittman, D. G., Kafonek, S. D., & Scott, R. C. (2001) · American Heart Journal · doi:10.1067/mhj.2001.114372 · Cited by 40
Grundy, S. M., Balady, G. J., Criqui, M. H., Fletcher, G., Greenland, P., Hiratzka, L. F., Houston-Miller, N., Kris-Etherton, P., Krumholz, H. M., LaRosa, J. C., et al. (1998) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · Cited by 40
Lesaffre, E. M. E. H., Kocmanová, D., Lemos, P. A., Disco, C. M. C., & Serruys, P. W. J. C. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80285-0 · Cited by 39
A community based stroke register in a high risk area for stroke in north west England.
Du, X. L., Sourbutts, J., Cruickshank, K. J., Summers, A., Roberts, N., Walton, E., & Holmes, S. (1997) · Journal of Epidemiology & Community Health · doi:10.1136/jech.51.5.472 · Cited by 38
Efficacy of Atorvastatin Compared With Simvastatin in Patients With Hypercholesterolemia
Farnier, M., Portal, J.-J., & Maigret, P. (2000) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424840000500104 · Cited by 38
Atorvastatin and simvastatin reduce elevated cholesterol in non-insulin dependent diabetes
Best, J. D., Nicholson, G. C., O'Neal, D., Kotowicz, M. A., Tebbutt, N., Chan, K., & Sanders, K. M. (1996) · Figshare · Cited by 37
Frequency of creatine kinase elevation during treatment with fluvastatin
Benghozi, R., Bortolini, M., Jia, Y., Isaacsohn, J. L., Troendle, A. J., & Gonasun, L. M. (2002) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)02209-3 · Cited by 36
Cost effectiveness of HMG-CoA reductase inhibition in Canada.
Russell, M. W., Huse, D. M., Miller, J. D., Kraemer, D. F., & Hartz, S. C. (2001) · PubMed · Cited by 36
Short‐Term Efficacy and Safety of Extended‐Release Fluvastatin in a Large Cohort of Elderly Patients
Bruckert, E., Lièvre, M., Giral, P., Crepaldi, G., Masana, L., Vrolix, M., Leitersdorf, E., & Dejager, S. (2003) · The American Journal of Geriatric Cardiology · doi:10.1111/j.1076-7460.2003.02000.x · Cited by 35
Jilma, B., Joukhadar, C., Derhaschnig, U., Rassoul, F., Richter, V., Wolzt, M., Dorner, G. T., Petternel, V., & Wagner, O. F. (2003) · Clinical Science · doi:10.1042/cs20020168 · Cited by 35
Wierzbicki, A. S., Reynolds, T., Gill, K., Alg, S., & Crook, M. A. (2000) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/204748730000700111 · Cited by 34
Cost-effectiveness of simvastatin in the secondary prevention of coronary artery disease in Canada.
Rivière, M., Wang, S., Leclerc, C., Fitzsimon, C., & Tretiak, R. (1997) · Europe PMC (PubMed Central) · Cited by 33
Recto, C. S., Acosta, S., & Dobs, A. S. (2000) · Clinical Cardiology · doi:10.1002/clc.4960230910 · Cited by 33
Insull, W., Black, D. M., Dujovne, C. A., Hosking, J. D., Hunninghake, D. B., Keilson, L., Knopp, R. H., McKenney, J. M., Stein, E. A., & Troendle, A. J. (1994) · PubMed · Cited by 33
Jukema, J. W. (1996) · ACC Current Journal Review · doi:10.1016/1062-1458(96)86728-6 · Cited by 33
Foley, D. P., Bonnier, H. J. R. M., Jackson, G., Macaya, C., Shepherd, J., Vrolix, M., & Serruys, P. W. J. C. (1994) · The American Journal of Cardiology · doi:10.1016/0002-9149(94)90633-5 · Cited by 32
Oranje, W. A., Sels, J.-P. J. E., Rondas-Colbers, G. J. W. M., Lemmens, P. J. M. R., & Wolffenbuttel, B. H. R. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00549-6 · Cited by 31
Sposito, A. C., Santos, R. D., Amâncio, R. F., Ramires, J. A. F., Chapman, M. J., & Maranhão, R. C. (2003) · Atherosclerosis · doi:10.1016/s0021-9150(02)00334-9 · Cited by 31
Okazaki, S., Yokoyama, T., & Miyauchi, K. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2004.11.005 · Cited by 31
A Multicenter, Placebo-Controlled, Dose-Ranging Study of Atorvastatin
Schrott, H. G., Fereshetian, A. G., Knopp, R. H., Bays, H. E., Jones, P. H., Littlejohn, T. W., McLain, R. W., & Black, D. M. (1998) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849800300204 · Cited by 29
Glasziou, P., Eckermann, S. D., Mulray, S. E., Simes, R. J., Martin, A. J., Kirby, A. C., Caleo, S., Hall, J. P., White, H. D., & Tonkin, A. M. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04883.x · Cited by 28
Cholesterol Reduction: Weighing the Benefits and Risks
Gaziano, J. M., Hebert, P., & Hennekens, C. (1996) · Annals of Internal Medicine · doi:10.7326/0003-4819-124-10-199605150-00009 · Cited by 28
Efficacy and safety of fluvastatin therapy for hypercholesterolemia after heart transplantation
O'Rourke, B. P., Barbir, M., Mitchell, A. G., Yacoub, M. H., & Banner, N. R. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2003.04.009 · Cited by 26
Boquist, S., Karpe, F., Danell-Toverud, K., & Hamsten, A. (2002) · Atherosclerosis · doi:10.1016/s0021-9150(01)00689-x · Cited by 25
Ballantyne, C. M., McKenney, J. E., & Trippe, B. S. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)01076-6 · Cited by 25
Wang, K., & Ting, C.-T. (2001) · Japanese Heart Journal · doi:10.1536/jhj.42.725 · Cited by 25
Tanaka, A., Yamada, N., Saitō, Y., Kawakami, M., Ohashi, Y., & Akanuma, Y. (2001) · Clinica Chimica Acta · doi:10.1016/s0009-8981(01)00589-7 · Cited by 25
TWENTY YEARS' EXPERIENCE OF MYOCARDIAL INFARCTION: THE VALUE OF A HEART ATTACK REGISTER
Gray, D. P., & Hampton, J. R. (1993) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.1993.tb09709.x · Cited by 24
Incidence of coronary heart disease in a health authority in London: review of a community register
Sutcliffe, S. J., Fox, K. F., Wood, D. A., Sutcliffe, A., Stock, K. J., Wright, M., Akhras, F., & Langford, E. (2003) · BMJ · doi:10.1136/bmj.326.7379.20 · Cited by 24
KEECH, A. C., Armitage, J., Wallendszus, K., LAWSON, A., HAUER, A. J., Parish, S., & Collins, R. (1996) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1996.tb00012.x · Cited by 24
Safety and efficacy of atorvastatin in patients with severe renal dysfunction
Holmberg, B., Brännström, M., Bucht, B., Crougneau, V., Dimény, E., Ekspong, A., Granroth, B., Gröntoft, K., Hadimeri, H., Ingman, B., et al. (2005) · Scandinavian Journal of Urology and Nephrology · doi:10.1080/00365590510031255 · Cited by 24
JACOTOT, B., Banga, J. D., Pfister, P., & Mehra, M. R. (1994) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.1994.tb04350.x · Cited by 24
OLSSON, A. G. (2001) · Clinical Therapeutics · doi:10.1016/s0149-2918(01)80029-1 · Cited by 24
Wilson, K., Marriott, J. F., Fuller, S., Lacey, L. A., & Gillen, D. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321001-00001 · Cited by 24
Efficacy of Atorvastatin in Primary Hypercholesterolemia
(1997) · The American Journal of Cardiology · doi:10.1016/s0002-9149(97)00092-1 · Cited by 24
Athyros, V. G., Papageorgiou, A. A., Hatzikonstandinou, H. A., Athyrou, V. V., & Kontopoulos, A. G. (1998) · Clinical Drug Investigation · doi:10.2165/00044011-199816030-00006 · Cited by 23
Muscari, A., Bastagli, L., Poggiopollini, G., Tomassetti, V., Massarelli, G., Boni, P., & Puddu, P. (2001) · Cardiovascular Drugs and Therapy · doi:10.1023/a:1013314227857 · Cited by 22
Leitersdorf, E., Muratti, E. N., Eliav, O., & Peters, T. K. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80025-6 · Cited by 22
Betteridge, D. J. (2004) · Atherosclerosis · doi:10.1016/s0021-9150(04)90462-5 · Cited by 22
Hemostatic Effects of Atorvastatin versus Simvastatin
Kadıköylü, G., Yükselen, V., Yavaşoğlu, İ., & Bolaman, Z. (2003) · Annals of Pharmacotherapy · doi:10.1345/aph.1c189 · Cited by 22
Sardo, M. A., Castaldo, M., Cinquegrani, M., Bonaiuto, M., Maesano, A., Versace, A. G., Spadaro, M., Campo, S., Nicocia, G., Altavilla, D., et al. (2002) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/107602960200800310 · Cited by 21
Quality of life assessment in peripheral arterial disease
Hiatt, W. R. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)06124-8 · Cited by 19
The Health and Activities Limitation Index in patients with acute myocardial infarction
Bradley, C. J., Kroll, J., & Holmes-Rovner, M. M. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00219-x · Cited by 19
Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia
Hunninghake, D. B., Insull, W., Knopp, R. H., Davidson, M. H., Lohrbauer, L. A., Jones, P. J. H., & Kafonek, S. D. (2001) · The American Journal of Cardiology · doi:10.1016/s0002-9149(01)01805-7 · Cited by 19
Postmarketing surveillance—lack of vigilance, lack of trust
Fontanarosa, P., Rennie, D., & DeAngelis, C. D. (2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.04.002 · Cited by 18
Isaacsohn, J. L., LaSalle, J. R., Chao, G., & Gonasun, L. M. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)80113-3 · Cited by 17
McCrindle, B. W., Ose, L., & Marais, D. (2003) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.09.056 · Cited by 16
Mondillo, S., Piercarlo, B., & Barbati, R. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00264-2 · Cited by 16
Wolffenbuttel, B. H. R. (1998) · The Netherlands Journal of Medicine · doi:10.1016/s0300-2977(97)00092-2 · Cited by 16
Cost‐effectiveness of prescribing statins according to Pharmaceutical Benefits Scheme criteria
Lim, S. S., Vos, T., Peeters, A., Liew, D., & McNeil, J. J. (2001) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2001.tb143676.x · Cited by 15
Low blood cholesterol and non-atherosclerotic disease mortality: where do we stand?
Smith, G. D. (1997) · European Heart Journal · doi:10.1093/oxfordjournals.eurheartj.a015118 · Cited by 15
Intervention, D. A. L. (2002) · Clinical Diabetology · Cited by 15
Percutaneous coronary intervention versus medical therapy for coronary heart disease
Maron, D. J. (2000) · Current Atherosclerosis Reports · doi:10.1007/s11883-000-0061-9 · Cited by 14
Medical management of unstable angina
Cairns, J. (1995) · The Lancet · doi:10.1016/s0140-6736(95)92834-0 · Cited by 14
Treatment of heterozygous familial hypercholesterolemia: atorvastatin vs simvastatin.
Bo, M., Nicolello, M. T., Fiandra, U., Mercadante, G., Piliego, T., & Fabris, F. M. (2001) · PubMed · Cited by 13
Issues in Statin-Associated Myopathy—Reply
Luh, J. Y., & Karnath, B. M. (2003) · JAMA · doi:10.1001/jama.290.7.888-c · Cited by 13
Efficacy and Safety of Fluvastatin in Women with Primary Hypercholesterolaemia
Peters, T. K., Muratti, E. N., & Mehra, M. R. (1994) · Drugs · doi:10.2165/00003495-199400472-00012 · Cited by 13
Baggio, G., De Candia, O., Forte, P. L., Mello, F., Andriolli, A., Donazzan, S., Valerio, G., Milani, M., & Crepaldi, G. (1994) · Drugs · doi:10.2165/00003495-199400472-00011 · Cited by 12
Franken, A., Wolffenbuttel, B. H. R., & Vincent, H. K. (2004) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(04)90511-4 · Cited by 12
Tomlinson, B., Mak, T. W. L., Tsui, J. Y. Y., Woo, J., Shek, C. C., Critchley, J., & Masarei, J. R. L. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80036-0 · Cited by 11
Efficacy and safety of atorvastatin and pravastatin in patients with hypercholesterolemia
Assmann, G., Hüwel, D., Schussmann, K., Smilde, J. G., Kösling, M., Withagen, A. J. A. M., Wunderlich, J., Stoel, I., van Dormaal, J. J., Neuss, J., et al. (1999) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(99)00011-4 · Cited by 11
Cost effectiveness of statins for the secondary prevention of coronary heart disease in Ireland.
Barry, M. G., & Heerey, A. M. (2002) · PubMed · Cited by 11
Dallongeville, J., Fruchart, J., Maigret, P., Bertolini, S., Bon, G. B., Campbell, M. M., Farnier, M., Langan, J., Mahla, G., Pauciullo, P., et al. (1998) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/107424849800300202 · Cited by 10
(2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000148213.27327.8c · Cited by 10
(2004) · Obstetrics and Gynecology · doi:10.1097/01.aog.0000143130.12709.b4 · Cited by 10
Insull, W. (1994) · Archives of Internal Medicine · doi:10.1001/archinte.154.21.2449 · Cited by 9
Berne, C., & Siewert-Delle, A. (2004) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(04)90461-3 · Cited by 8
Branchi, A., Fiorenza, A. M., Torri, A., Muzio, F., Rovellini, A., Berra, C., & Sommariva, D. (2001) · Current Therapeutic Research · doi:10.1016/s0011-393x(01)89005-6 · Cited by 8
Sato, S., Kobayashi, T., Awata, N., Reiber, J. H. C., Nakagawa, Y., Hiraoka, H., Katoh, O., Kirino, M., Kobayashi, T., Iida, M., et al. (2001) · Current Therapeutic Research · doi:10.1016/s0011-393x(01)80058-8 · Cited by 8
Berto, P., Munro, V., Gaddi, A. V., Negrini, C., Hutton, J., & Mast, O. (2000) · Clinical Drug Investigation · doi:10.2165/00044011-200020020-00006 · Cited by 8
Yeo, W. W., & Yeo, W. W. (2002) · Heart · doi:10.1136/heart.87.5.423 · Cited by 8
Self-citationOvercoming the obstacles — the outsider's view
Furnham, A. F. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)00256-7 · Cited by 7
Clinical efficacy of fluvastatin for hyperlipidemia in Japanese patients
Teramoto, T., Goto, Y., Kurokawa, K., Nakamura, H., Yoshida, S., Saito, Y., Nakaya, N., Itakura, H., Takaku, F., Yamada, N., et al. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(05)80013-x · Cited by 7
Bertrand, M., Mcfadden, E., Fruchart, J., Belle, É. V., Commeau, P., Grollier, G., Bassand, J., Machecourt, J., Cassagnes, J., Mossard, J., et al. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00259-3 · Cited by 6
Fluvastatin titrate-to-goal clinical practice study: Interim results
Marcus, A. O. (2009) · Clinical Cardiology · doi:10.1002/clc.4960171605 · Cited by 6
Insull, W., Troendle, A. J., Silvers, A., & Dunne, C. (1995) · Atherosclerosis · doi:10.1016/0021-9150(95)96604-q · Cited by 6
KEECH, A. C., Colquhoun, D., Arulchelvam, M., Simes, R. J., & Tonkin, A. M. (1999) · Atherosclerosis · doi:10.1016/s0021-9150(99)80129-4 · Cited by 6
Vansant, G. A. A. M., Mertens, A. C., & Muls, E. (2001) · Acta Cardiologica · doi:10.2143/ac.56.3.2005634 · Cited by 6
Mueck, A. O., & Seeger, H. (2002) · The Journal of the British Menopause Society · doi:10.1258/136218002100321839 · Cited by 6
Mehra, M. R., Uber, P. A., & Vivekananthan, K. (2003) · ACC Current Journal Review · doi:10.1016/s1062-1458(03)00067-9 · Cited by 6
Ballantyne, C. M. (1999) · Current Atherosclerosis Reports · doi:10.1007/s11883-999-0043-5 · Cited by 5
M.542 LDL-C/HDL-C ratio in patients with coronary artery disease and low HDL-C: The radar study
Jukema, J. W., Liem, A. H., Dunselman, P. H. J. M., van der Sloot, J. A. P., Lok, D. J. A., & Zwinderman, A. H. (2004) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(04)90540-0 · Cited by 5
Cost-effectiveness of treating hyperlipidemia in the presence of diabetes. Who should be treated?
Grover, S. A., Coupal, L., Zowall, H., & Dorais, M. (2001) · ACC Current Journal Review · doi:10.1016/s1062-1458(00)00171-9 · Cited by 5
Buzzi, A. P., & Pastore, M. A. (1997) · Current Therapeutic Research · doi:10.1016/s0011-393x(97)80068-9 · Cited by 4
Insull, W., Marais, A. D., Aronson, R., Manfreda, S., Bédard, J., Bowman, S. M., Browne, H., Burgess, L. J., Carr, A. A., Corn, L. G., et al. (2004) · British Journal of Cardiology · Cited by 4
Coronary heart disease prevention: insights from modelling incremental cost effectiveness
British Medical Journal Publishing Group (2004) · BMJ · doi:10.1136/bmj.328.7433.209 · Cited by 4
Coronary Risk Versus Cardiovascular Risk for Treatment Decisions in Mild Hypertension
Yeo, W. W., & Yeo, K. R. (2002) · European Journal of Cardiovascular Prevention & Rehabilitation · doi:10.1177/174182670200900508 · Cited by 3
Self-citationLDL-C/HDL-C ratio in patients with coronary artery disease and low HDL-C: the RADAR study
Jukema, J. W., & Liem, A. H. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-504x.2005.0538d.x · Cited by 2
Should rosuvastatin be withdrawn from the market?
Olsson, G. O., & Fox, J. C. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17305-4 · Cited by 2
Cost effectiveness of statins: are the differences really important?
Greener, M. (1998) · Inpharma Weekly · doi:10.2165/00128413-199811620-00010 · Cited by 2
Patent expiries: How should they affect prescribing advice?
Thompson, A. J. (2003) · eCite Digital Repository (University of Tasmania) · Cited by 2
110 Elderly patients with hypercholesterolaemia: results with fluvastatin
Lye, M., Valácio, R. A., Reckless, J. P. D., Ghosh, A. K., Findlay, I. N., Ghosh, M. K., Passmore, P., & Fulcher, R. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)87533-8 · Cited by 1
Tomlinson, B., Mak, T. W. L., Tsui, J. Y. Y., Woo, J., Shek, C. C., Critchley, J., & Masarei, J. R. L. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)94284-6 · Cited by 1
Ceballos-Díaz, C., Aristequi, R., & Hernández, G. (1997) · Atherosclerosis · doi:10.1016/s0021-9150(97)88320-7 · Cited by 1
Rosuvastatin: do we need another statin?
Ho, C. (2001) · PubMed · Cited by 1
Clinical efficacy of fluvastatin for hyperlipidemia in japanese patients
TAMIO, T., YUICHIRO, G., Kiyoshi, K., HARUO, N., SHO, Y., YASUSHI, S., NORIAKI, N., HIROSHIGE, I., FUMIMARO, T., & NOBUHIRO, Y. (1995) · The American Journal of Cardiology · doi:10.1016/s0002-9149(06)80007-x · Cited by 1
Muzio, B. P. D., Agazzi, G. M., & Sharma, R. (2015) · Radiopaedia.org · doi:10.53347/rid-41796 · Cited by 1
Research works printed but not linked: 20
- Sproston K, Primatesta P. Health Survey for England 2003. Vol. 1. Cardiovascular disease. London: Department of Health; 2004.
- Gibbs RGJ, Newson R, Lawrenson R, Greenhalgh RM, Davies AH. Diagnosis and initial management of stroke and transient ischemic attack across UK health regions from 1992 to 1996: experience of a national primary care database. Stroke 2001;32:1085-90.
- Corvol JC, Bouzamondo A, Sirol M, Hulot JS, Sanchez P, Lechat P. Differential effects of lipid- lowering therapies on stroke prevention: a meta- analysis of randomized trials. Arch Intern Med 2003;163:669-76.
- National Statistics. Mortality statistics: cause. Review of the Registrar General on deaths by cause, sex and age, in England and Wales, 2001. DH2 No. 28. London: Office for National Statistics; 2003. References
- Hackett ML, Duncan JR, Anderson CS, Broad JB, Bonita R. Health-related quality of life among long-term survivors of stroke: results from the Auckland Stroke Study, 1991-1992. Stroke 2000; 31:440-7.
- Goyder E, McBeath S, Sims A, Ashwell S, Sherry R. Quantifying the gap between policy and practice in cardiovascular risk reduction. A review of the evidence from recent cardiovascular and diabetes audits in the UK. Oxford: South East Public Health Observatory and Trent Public Health Observatory; 2003.
- Dr Foster's case notes: Prescribing of lipid regulating drugs and admissions for myocardial infarction in England. BMJ 2004;329:645.
- Committee on Safety of Medicines. Statins and cytochrome P450 interactions. Current Problems in Pharmacovigilance 2004;30:1-2.
- Cranney A, Tugwell P, Wells G, Guyatt G. Systematic reviews of randomized trials in osteoporosis: introduction and methodology. Endocr Rev 2002;23:497-507.
- Stephenson BJ, Rowe BH, Haynes RB, Macharia WM, Leon G. Is this patient taking the treatment as prescribed? JAMA 1993;269:2779-81.
- Voss S, Quail D, Dawson A, Backstrom T, Aguas F, Erenus M, et al. A randomised, double-blind trial comparing raloxifene HCI and continuous combined hormone replacement therapy in postmenopausal women: effects on compliance and quality of life. BJOG 2002;109:874-85.
- McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA 2002;288:2868-79.
- Howell N, Trotter R, Mottram DR, Rowe PH. Compliance with statins in primary care. Pharmaceutical Journal 2004;272:23-6.
- Ross SD, Allen IE, Connelly JE, Korenblat BM, Smith ME, Bishop D, Luo D. Clinical outcomes in statin treatment trials: a meta-analysis. Arch Intern Med 1999;159:1793-802.
- Review Manager (RevMan). URL: http://www.cc-ims.net/RevMan. Accessed September 2000.
- Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
- Olsson AG, Eriksson M, Johnson O, Kjellstrom T, Lanke J, Larsen ML, et al. 3-Study Investigators. A 52-week, multicenter, randomized, parallel- group, double-blind, double-dummy study to assess the efficacy of atorvastatin and simvastatin in reaching low-density lipoprotein cholesterol and triglyceride targets: the Treat-to-Target (3T) study. Clin Ther 2003;25:119-38.
- Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, Stalenhoef AF. Effect of aggressive versus conventional lipid lowering on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, double-blind trial. Lancet 2001; 357:577-81.
- Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
- Bestehorn HP, Rensing UF, Roskamm H, Betz P, Benesch L, Schemeitat K, et al. The effect of simvastatin on progression of coronary artery disease. The multicenter Coronary Intervention Study (CIS). Eur Heart J 1997;18:226-34.
Cited by
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz455 · Cited by 8,961
Mach, F., Baigent, C., Catapano, A. L., Koskinas, K. C., Casula, M., Badimon, L., Chapman, M. J., De Backer, G. G., Delgado, V., Ference, B. A., et al. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.08.014 · Cited by 4,854
“In primary ASCVD prevention, the evidence indicates that generic statin-based treatments are cost-effective for people at least down to 1% annual total CVD risk and could be cost-effective at even lower risk,(589) with the highest tolerated statin dose likely the most costeffective.(591,593,594) Importantly, many pati…”
2016 ESC/EAS Guidelines for the Management of Dyslipidaemias
Catapano, A. L., Graham, I., De Backer, G., Wiklund, O., Chapman, M. J., Drexel, H., Hoes, A. W., Jennings, C. S., Landmesser, U., Pedersen, T. R., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw272 · Cited by 3,162
Statins for the primary prevention of cardiovascular disease
Taylor, F., Huffman, M. D., Macedo, A. F., Moore, T. H., Burke, M., Davey Smith, G., Ward, K., Ebrahim, S., & Gay, H. C. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004816.pub5 · Cited by 1,934
Cipriani, A., Furukawa, T. A., Salanti, G., Geddes, J. R., Higgins, J. P., Churchill, R., Watanabe, N., Nakagawa, A., Omori, I. M., McGuire, H., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60046-5 · Cited by 1,654
Metadata
- Authors
- Ward, S., Lloyd Jones, M., Pandor, A., Holmes, M., Ara, R., Ryan, A., Yeo, W., & Payne, N.
- Affiliations
- University of Sheffield (GB)
- University of Southampton (GB)
- Royal Hallamshire Hospital (GB)
- Venue
- Health Technology Assessment
- Published
- 2007-04
- Volume
- 11
- Issue
- 14
- Pages
- 1-160, iii
- ISSN
- 1366-5278 (ISSN-L)
- 2046-4924
- OpenAlex
- W2048859524
- Cited by
- 556
- References
- 356
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 10 · 2023: 6 · 2022: 10 · 2021: 16 · 2020: 25 · 2019: 21 · 2018: 20 · 2017: 34 · 2016: 39 · 2015: 54 · 2014: 45 · 2013: 46 · 2012: 58
- FWCI
- 5.90
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Locations
- Health Technology Assessment (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Health Technology Assessment programme (03/30/01)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Coronary Interventions and Diagnostics
- Keywords
- statins, coronary artery disease, cardiovascular disease prevention, primary prevention, secondary prevention, cost-effectiveness, cardiovascular mortality, myocardial infarction, stroke, statin safety, rhabdomyolysis, hepatotoxicity, atorvastatin, pravastatin, simvastatin, fluvastatin, Markov model, quality-adjusted life years
- MeSH terms
- Bayes Theorem, Coronary Disease, Cost-Benefit Analysis, Female, Humans, Male, Quality of Life, Meta-Analysis as Topic, Hydroxymethylglutaryl-CoA Reductase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.